1. Home >
  2. M&A >
  3. Merger >
  4. United States >
  5. Massachusetts >
  6. Arsanis Acquires X4 Pharmaceuticals

M&A Deal Summary

Arsanis Acquires X4 Pharmaceuticals

On November 27, 2018, Arsanis acquired life science company X4 Pharmaceuticals

Acquisition Highlights
  • This is Arsanis’ 1st transaction in the Life Science sector.
  • This is Arsanis’ 1st transaction in the United States.
  • This is Arsanis’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2018-11-27
Target X4 Pharmaceuticals
Sector Life Science
Buyer(s) Arsanis
Deal Type Merger
Advisor(s) Stifel (Financial)
Mintz Levin Cohn Ferris Glovsky and Popeo (Legal)

Target

X4 Pharmaceuticals

Cambridge, Massachusetts, United States
X4 Pharmaceuticals, Inc. is the developer of a novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer. X4’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate, X4P-001, is in Phase 2 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease, and is currently under investigation in multiple clinical trials in solid tumors.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Arsanis

Waltham, Massachusetts, United States
Category Company
Founded 2010
Sector Life Science
Employees43
DESCRIPTION

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Arsanis possesses a deep understanding of the pathogenesis of infection, paired with access to what Arsanis believes to be some of the most advanced mAb discovery techniques and platforms available today. Arsanis’ pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including a respiratory syncytial virus. Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with a wholly owned subsidiary that is primarily focused on discovery research in Vienna, Austria (Arsanis Biosciences GmbH).

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Merger M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2018 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal